{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:24:45Z","timestamp":1791998685227,"version":"4.4.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00134-025-08155-x","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T14:13:02Z","timestamp":1761142382000},"page":"2289-2304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Life-threatening immune-related adverse events in the intensive care unit: a narrative review"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1316-3517","authenticated-orcid":false,"given":"Samuel","family":"Pichon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadi","family":"Zebian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Merlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Lionet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ledoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massih","family":"Ningarhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"8155_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00134-019-05653-7","volume":"45","author":"M Darmon","year":"2019","unstructured":"Darmon M, Bourmaud A, Georges Q et al (2019) Changes in critically ill cancer patients\u2019 short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. Intensive Care Med 45:977\u2013987. https:\/\/doi.org\/10.1007\/s00134-019-05653-7","journal-title":"Intensive Care Med"},{"key":"8155_CR2","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","volume":"31","author":"E Azoulay","year":"2013","unstructured":"Azoulay E, Mokart D, P\u00e8ne F et al (2013) Outcomes of critically Ill patients with hematologic malignancies: prospective multicenter data from france and belgium\u2014a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study. J Clin Oncol 31:2810\u20132818. https:\/\/doi.org\/10.1200\/JCO.2012.47.2365","journal-title":"J Clin Oncol"},{"key":"8155_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"H-Y Min","year":"2022","unstructured":"Min H-Y, Lee H-Y (2022) Molecular targeted therapy for anticancer treatment. Exp Mol Med 54:1670\u20131694. https:\/\/doi.org\/10.1038\/s12276-022-00864-3","journal-title":"Exp Mol Med"},{"key":"8155_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"8155_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"8155_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B et al (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective. eClinicalMedicine 70:102536. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102536","journal-title":"eClinicalMedicine"},{"key":"8155_CR7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"8155_CR8","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D et al (2023) Immune checkpoint therapy\u2014current perspectives and future directions. Cell 186:1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","journal-title":"Cell"},{"key":"8155_CR9","doi-asserted-by":"publisher","first-page":"1447021","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG et al (2024) Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15:1447021. https:\/\/doi.org\/10.3389\/fimmu.2024.1447021","journal-title":"Front Immunol"},{"key":"8155_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"8155_CR11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","volume":"161","author":"SC Sasson","year":"2021","unstructured":"Sasson SC, Slevin SM, Cheung VTF et al (2021) Interferon-gamma-producing cd8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology 161:1229-1244.e9. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.025","journal-title":"Gastroenterology"},{"key":"8155_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM et al (2022) T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature 611:818\u2013826. https:\/\/doi.org\/10.1038\/s41586-022-05432-3","journal-title":"Nature"},{"key":"8155_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.13727","volume":"8","author":"K Fletcher","year":"2025","unstructured":"Fletcher K, Machaalani M, El Hajj CR et al (2025) Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open 8:e2513727. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.13727","journal-title":"JAMA Netw Open"},{"key":"8155_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210031","volume":"103","author":"G Beecher","year":"2024","unstructured":"Beecher G, Pinal-Fernandez I, Mammen AL, Liewluck T (2024) Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy. Neurology 103:e210031. https:\/\/doi.org\/10.1212\/WNL.0000000000210031","journal-title":"Neurology"},{"key":"8155_CR15","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"8155_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK et al (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"8155_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","volume":"25","author":"G Wan","year":"2024","unstructured":"Wan G, Chen W, Khattab S et al (2024) Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol 25:1053\u20131069. https:\/\/doi.org\/10.1016\/S1470-2045(24)00278-X","journal-title":"Lancet Oncol"},{"key":"8155_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf682","author":"J-E Salem","year":"2025","unstructured":"Salem J-E, Ajrouche A, Rozes A et al (2025) Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf682","journal-title":"Eur Heart J"},{"key":"8155_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"J-E Salem","year":"2023","unstructured":"Salem J-E, Bretagne M, Abbar B et al (2023) Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 13:1100\u20131115. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"},{"key":"8155_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","volume":"50","author":"L Plomp","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D et al (2025) Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health - Eur 50:101192. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101192","journal-title":"Lancet Reg Health - Eur"},{"key":"8155_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem J-E et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140:80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"key":"8155_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G et al (2023) Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation 148:473\u2013486. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.062405","journal-title":"Circulation"},{"key":"8155_CR23","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation ( HFA ), the E uropean A ssociation of C ardiovascular I maging ( EACVI ) and the Cardio-Oncology C ouncil of the E uropean S ociety of C ardiology ( ESC ). Eur J Heart Fail 22:1504\u20131524. https:\/\/doi.org\/10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"key":"8155_CR24","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41:1733\u20131743. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051","journal-title":"Eur Heart J"},{"key":"8155_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf315","author":"JR Power","year":"2025","unstructured":"Power JR, Dolladille C, Ozbay B et al (2025) Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf315","journal-title":"Eur Heart J"},{"key":"8155_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","volume":"7","author":"A Saade","year":"2019","unstructured":"Saade A, Mansuet-Lupo A, Arrondeau J et al (2019) Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer 7:266. https:\/\/doi.org\/10.1186\/s40425-019-0760-4","journal-title":"J Immunother Cancer"},{"key":"8155_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9:e002890. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"8155_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12660-2","author":"S Pichon","year":"2024","unstructured":"Pichon S, Aigrain P, Lacombe C et al (2024) Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12660-2","journal-title":"J Neurol"},{"key":"8155_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad169","volume":"5","author":"A Farina","year":"2023","unstructured":"Farina A, Birzu C, Elsensohn M-H et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5:fcad169. https:\/\/doi.org\/10.1093\/braincomms\/fcad169","journal-title":"Brain Commun"},{"key":"8155_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab220","volume":"3","author":"L Pla\u00e7ais","year":"2021","unstructured":"Pla\u00e7ais L, Michot J-M, Champiat S et al (2021) Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun 3:fcab220. https:\/\/doi.org\/10.1093\/braincomms\/fcab220","journal-title":"Brain Commun"},{"key":"8155_CR31","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","volume":"22","author":"E Fonseca","year":"2023","unstructured":"Fonseca E, Cabrera-Maqueda JM, Ruiz-Garc\u00eda R et al (2023) Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol 22:1150\u20131159. https:\/\/doi.org\/10.1016\/S1474-4422(23)00335-6","journal-title":"Lancet Neurol"},{"key":"8155_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16:535\u2013548. https:\/\/doi.org\/10.1038\/s41571-019-0194-4","journal-title":"Nat Rev Clin Oncol"},{"key":"8155_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101011","volume":"44","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Fourier A et al (2024) Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. Lancet Reg Health Eur 44:101011. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101011","journal-title":"Lancet Reg Health Eur"},{"key":"8155_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","volume":"10","author":"Q Su","year":"2019","unstructured":"Su Q, Zhu EC, Wu J-B et al (2019) Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. Front Immunol 10:108. https:\/\/doi.org\/10.3389\/fimmu.2019.00108","journal-title":"Front Immunol"},{"key":"8155_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170503","volume":"134","author":"MI Ghanbar","year":"2024","unstructured":"Ghanbar MI, Suresh K (2024) Pulmonary toxicity of immune checkpoint immunotherapy. J Clin Invest 134:e170503. https:\/\/doi.org\/10.1172\/JCI170503","journal-title":"J Clin Invest"},{"key":"8155_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35:709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"key":"8155_CR37","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0012-2019","volume":"28","author":"M Delaunay","year":"2019","unstructured":"Delaunay M, Pr\u00e9vot G, Collot S et al (2019) Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev 28:190012. https:\/\/doi.org\/10.1183\/16000617.0012-2019","journal-title":"Eur Respir Rev"},{"key":"8155_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001731","volume":"9","author":"A Balaji","year":"2021","unstructured":"Balaji A, Hsu M, Lin CT et al (2021) Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer 9:e001731. https:\/\/doi.org\/10.1136\/jitc-2020-001731","journal-title":"J Immunother Cancer"},{"key":"8155_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12890-024-03284-3","volume":"24","author":"M Karayama","year":"2024","unstructured":"Karayama M, Inui N, Inoue Y et al (2024) Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study. BMC Pulm Med 24:495. https:\/\/doi.org\/10.1186\/s12890-024-03284-3","journal-title":"BMC Pulm Med"},{"key":"8155_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014","journal-title":"Eur J Cancer"},{"key":"8155_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer Oxf Engl 103:7\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129","journal-title":"Eur J Cancer Oxf Engl"},{"key":"8155_CR42","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot J-M, Comont T et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6:e48\u2013e57. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"key":"8155_CR43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2019003886","volume":"135","author":"P Liu","year":"2020","unstructured":"Liu P, Pan X, Chen C et al (2020) Nivolumab treatment of relapsed\/refractory Epstein-Barr virus\u2013associated hemophagocytic lymphohistiocytosis in adults. Blood 135:826\u2013833. https:\/\/doi.org\/10.1182\/blood.2019003886","journal-title":"Blood"},{"key":"8155_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","volume":"123","author":"VTF Cheung","year":"2020","unstructured":"Cheung VTF, Gupta T, Olsson-Brown A et al (2020) Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 123:207\u2013215. https:\/\/doi.org\/10.1038\/s41416-020-0882-y","journal-title":"Br J Cancer"},{"key":"8155_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/CMR.0000000000000878","volume":"33","author":"C Vuillamy","year":"2023","unstructured":"Vuillamy C, Arnault J-P, Fumery M et al (2023) Clostridium difficile infection and immune checkpoint inhibitor\u2013induced colitis in melanoma: 18 cases and a review of the literature. Melanoma Res 33:192\u2013198. https:\/\/doi.org\/10.1097\/CMR.0000000000000878","journal-title":"Melanoma Res"},{"key":"8155_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.07.005","author":"LM Braun","year":"2025","unstructured":"Braun LM, Lu Y, Zeiser R (2025) Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. Trends Cancer. https:\/\/doi.org\/10.1016\/j.trecan.2025.07.005","journal-title":"Trends Cancer"},{"key":"8155_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000278","volume":"3","author":"MH Geukes Foppen","year":"2018","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S et al (2018) Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3:e000278. https:\/\/doi.org\/10.1136\/esmoopen-2017-000278","journal-title":"ESMO Open"},{"key":"8155_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002058","volume":"9","author":"F Zou","year":"2021","unstructured":"Zou F, Wang X, Glitza Oliva IC et al (2021) Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 9:e002058. https:\/\/doi.org\/10.1136\/jitc-2020-002058","journal-title":"J Immunother Cancer"},{"key":"8155_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/CJI.0000000000000472","volume":"46","author":"S Kramer","year":"2023","unstructured":"Kramer S, van Hee K, Blokzijl H et al (2023) Immune checkpoint inhibitor-related pancreatitis: a case series, review of the literature and an expert opinion. J Immunother Hagerstown Md 46:271\u2013275. https:\/\/doi.org\/10.1097\/CJI.0000000000000472","journal-title":"J Immunother Hagerstown Md"},{"key":"8155_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100851","volume":"5","author":"E Atallah","year":"2023","unstructured":"Atallah E, Welsh SJ, O\u2019Carrigan B et al (2023) Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study. JHEP Rep Innov Hepatol 5:100851. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100851","journal-title":"JHEP Rep Innov Hepatol"},{"key":"8155_CR51","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/apt.18276","volume":"60","author":"L Hountondji","year":"2024","unstructured":"Hountondji L, Faure S, Palassin P et al (2024) Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM. Aliment Pharmacol Ther 60:1561\u20131572. https:\/\/doi.org\/10.1111\/apt.18276","journal-title":"Aliment Pharmacol Ther"},{"key":"8155_CR52","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver (2019) EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 70:1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"8155_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16198","volume":"45","author":"L Dara","year":"2025","unstructured":"Dara L, De Martin E (2025) Immune-mediated liver injury from checkpoint inhibitor: an evolving frontier with emerging challenges. Liver Int 45:e16198. https:\/\/doi.org\/10.1111\/liv.16198","journal-title":"Liver Int"},{"key":"8155_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.gastrohep.2023.10.009","volume":"47","author":"M Riveiro-Barciela","year":"2024","unstructured":"Riveiro-Barciela M, Carballal S, D\u00edaz-Gonz\u00e1lez \u00c1 et al (2024) Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH\u2013AEG\u2013SEPD\u2013SEOM\u2013GETECCU. Gastroenterol Hepatol 47:401\u2013432. https:\/\/doi.org\/10.1016\/j.gastrohep.2023.10.009","journal-title":"Gastroenterol Hepatol"},{"key":"8155_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/liv.15340","volume":"43","author":"P Berry","year":"2023","unstructured":"Berry P, Kotha S, Zen Y et al (2023) Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort. Liver Int Off J Int Assoc Study Liver 43:147\u2013154. https:\/\/doi.org\/10.1111\/liv.15340","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"8155_CR56","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/hep.30157","volume":"68","author":"J LoPiccolo","year":"2018","unstructured":"LoPiccolo J, Brener MI, Oshima K et al (2018) Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. Hepatology 68:2431\u20132433. https:\/\/doi.org\/10.1002\/hep.30157","journal-title":"Hepatology"},{"key":"8155_CR57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19:345\u2013361. https:\/\/doi.org\/10.1007\/s40257-017-0336-3","journal-title":"Am J Clin Dermatol"},{"key":"8155_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44272-025-00043-1","volume":"4","author":"Y Sun","year":"2025","unstructured":"Sun Y, Huang J, Hu F et al (2025) Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors (2025). Clin Cancer Bull 4:16. https:\/\/doi.org\/10.1007\/s44272-025-00043-1","journal-title":"Clin Cancer Bull"},{"key":"8155_CR59","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips GS, Wu J, Hellmann MD et al (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37:2746\u20132758. https:\/\/doi.org\/10.1200\/JCO.18.02141","journal-title":"J Clin Oncol"},{"key":"8155_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"8155_CR61","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17:389\u2013399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"8155_CR62","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.3390\/jcm12103468","volume":"12","author":"P Chen","year":"2023","unstructured":"Chen P, Li J, Tan H (2023) Progress and challenges of immune checkpoint inhibitor-induced hypophysitis. J Clin Med 12:3468. https:\/\/doi.org\/10.3390\/jcm12103468","journal-title":"J Clin Med"},{"key":"8155_CR63","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2337\/dc21-2213","volume":"45","author":"X Chen","year":"2022","unstructured":"Chen X, Affinati AH, Lee Y et al (2022) Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care 45:1170\u20131176. https:\/\/doi.org\/10.2337\/dc21-2213","journal-title":"Diabetes Care"},{"key":"8155_CR64","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","volume":"3","author":"H Seethapathy","year":"2021","unstructured":"Seethapathy H, Herrmann SM, Sise ME (2021) Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management. Kidney Med 3:1074\u20131081. https:\/\/doi.org\/10.1016\/j.xkme.2021.08.008","journal-title":"Kidney Med"},{"key":"8155_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435\u2013446. https:\/\/doi.org\/10.1681\/ASN.2019070676","journal-title":"J Am Soc Nephrol"},{"key":"8155_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","volume":"9","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME et al (2021) Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9:e003467. https:\/\/doi.org\/10.1136\/jitc-2021-003467","journal-title":"J Immunother Cancer"},{"key":"8155_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","volume":"8","author":"A Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz A, Amir E, Ng P et al (2020) Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 8:e000467. https:\/\/doi.org\/10.1136\/jitc-2019-000467","journal-title":"J Immunother Cancer"},{"key":"8155_CR68","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","volume":"107","author":"SM Herrmann","year":"2025","unstructured":"Herrmann SM, Abudayyeh A, Gupta S et al (2025) Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int 107:21\u201332. https:\/\/doi.org\/10.1016\/j.kint.2024.09.017","journal-title":"Kidney Int"},{"key":"8155_CR69","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"8155_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3721","author":"L Laurent","year":"2025","unstructured":"Laurent L, Abbar B, Bihan K et al (2025) Comedications associated with immune-related adverse events from immune-checkpoint inhibitors. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.3721","journal-title":"Clin Pharmacol Ther"},{"key":"8155_CR71","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcrc.2020.10.008","volume":"61","author":"Y Hourmant","year":"2021","unstructured":"Hourmant Y, Mailloux A, Valade S et al (2021) Impact of early ICU admission on outcome of critically ill and critically ill cancer patients: A systematic review and meta-analysis. J Crit Care 61:82\u201388. https:\/\/doi.org\/10.1016\/j.jcrc.2020.10.008","journal-title":"J Crit Care"},{"key":"8155_CR72","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00134-022-06617-0","volume":"48","author":"JN Darvall","year":"2022","unstructured":"Darvall JN, Bellomo R, Bailey M et al (2022) Impact of frailty on persistent critical illness: a population-based cohort study. Intensive Care Med 48:343\u2013351. https:\/\/doi.org\/10.1007\/s00134-022-06617-0","journal-title":"Intensive Care Med"},{"key":"8155_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/curroncol28010007","volume":"28","author":"R Holstead","year":"2020","unstructured":"Holstead R, Kartolo A, Baetz T (2020) Emergency department utilization for patients receiving immune checkpoint inhibitors: a retrospective analysis of identification and outcomes for those presenting for immune-related adverse events. Curr Oncol 28:52\u201359. https:\/\/doi.org\/10.3390\/curroncol28010007","journal-title":"Curr Oncol"},{"key":"8155_CR74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/qjmed\/hcac258","volume":"116","author":"T Cooksley","year":"2023","unstructured":"Cooksley T, Weaver JMJ, Haji-Michael P (2023) Intensive care unit requirements in patients treated with immune checkpoint inhibitors. QJM Int J Med 116:285\u2013287. https:\/\/doi.org\/10.1093\/qjmed\/hcac258","journal-title":"QJM Int J Med"},{"key":"8155_CR75","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/COC.0000000000000935","volume":"45","author":"M Leprince","year":"2022","unstructured":"Leprince M, Pourroy B, Boucekine M et al (2022) Severe immune checkpoint inhibitor toxicity leading to ICU admission in patients with solid tumors. Am J Clin Oncol 45:403\u2013404. https:\/\/doi.org\/10.1097\/COC.0000000000000935","journal-title":"Am J Clin Oncol"},{"key":"8155_CR76","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000468","volume":"46","author":"MCT Van Zeijl","year":"2023","unstructured":"Van Zeijl MCT, Van Breeschoten J, De Wreede LC et al (2023) Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nation-wide cohort of advanced melanoma patients in the Netherlands. J Immunother 46:197\u2013204. https:\/\/doi.org\/10.1097\/CJI.0000000000000468","journal-title":"J Immunother"},{"key":"8155_CR77","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","volume":"10","author":"A Joseph","year":"2020","unstructured":"Joseph A, Simonaggio A, Stoclin A et al (2020) Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Ann Intensive Care 10:143. https:\/\/doi.org\/10.1186\/s13613-020-00761-w","journal-title":"Ann Intensive Care"},{"key":"8155_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70264","volume":"45","author":"M Fortuny","year":"2025","unstructured":"Fortuny M, da Fonseca LG, Allaire M et al (2025) Breaking barriers for intensive care admission in patients with advanced HCC on immunotherapy. Liver Int Off J Int Assoc Study Liver 45:e70264. https:\/\/doi.org\/10.1111\/liv.70264","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"8155_CR79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13613-023-01122-z","volume":"13","author":"A-C Toffart","year":"2023","unstructured":"Toffart A-C, Meert A-P, Wallet F et al (2023) ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care 13:29. https:\/\/doi.org\/10.1186\/s13613-023-01122-z","journal-title":"Ann Intensive Care"},{"key":"8155_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7302","author":"L Lin","year":"2024","unstructured":"Lin L, Houwink API, van Dieren JM et al (2024) Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.7302","journal-title":"Cancer Med"},{"key":"8155_CR81","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcrc.2021.05.020","volume":"65","author":"P Rajendram","year":"2021","unstructured":"Rajendram P, Torbic H, Duggal A et al (2021) Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: a multi-center case series. J Crit Care 65:126\u2013132. https:\/\/doi.org\/10.1016\/j.jcrc.2021.05.020","journal-title":"J Crit Care"},{"key":"8155_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","volume":"10","author":"LS Nguyen","year":"2022","unstructured":"Nguyen LS, Bretagne M, Arrondeau J et al (2022) Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer 10:e004699. https:\/\/doi.org\/10.1136\/jitc-2022-004699","journal-title":"J Immunother Cancer"},{"key":"8155_CR83","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/IMCRJ.S507273","volume":"18","author":"Y Meng","year":"2025","unstructured":"Meng Y, Yuan Y, Ma L et al (2025) Extracorporeal membrane oxygenation for treatment of immune checkpoint inhibitor-related pneumonia complicated with severe ARDS: a case report. Int Med Case Rep J 18:411\u2013419. https:\/\/doi.org\/10.2147\/IMCRJ.S507273","journal-title":"Int Med Case Rep J"},{"key":"8155_CR84","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/ans.18485","volume":"93","author":"KDR Le","year":"2023","unstructured":"Le KDR, Choy KT, Roth S et al (2023) Immune mediated colitis: a surgical perspective. ANZ J Surg 93:1495\u20131502. https:\/\/doi.org\/10.1111\/ans.18485","journal-title":"ANZ J Surg"},{"key":"8155_CR85","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1016\/j.jhep.2020.10.024","volume":"75","author":"W Bernal","year":"2021","unstructured":"Bernal W, Karvellas C, Saliba F et al (2021) Intensive care management of acute-on-chronic liver failure. J Hepatol 75:S163\u2013S177. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.024","journal-title":"J Hepatol"},{"key":"8155_CR86","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13613-025-01517-0","volume":"15","author":"M Jourdain","year":"2025","unstructured":"Jourdain M, Chatti IG, Housni B et al (2025) Renal replacement therapy in an intensive care unit: guidelines from the SRLF-GFRUP consensus conference. Ann Intensive Care 15:100. https:\/\/doi.org\/10.1186\/s13613-025-01517-0","journal-title":"Ann Intensive Care"},{"key":"8155_CR87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson M-KND, Sonnemann HM et al (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6:51. https:\/\/doi.org\/10.1186\/s40425-018-0371-5","journal-title":"J Immunother Cancer"},{"key":"8155_CR88","doi-asserted-by":"publisher","first-page":"19896","DOI":"10.1074\/jbc.RA119.010379","volume":"294","author":"N Maeda","year":"2019","unstructured":"Maeda N, Maruhashi T, Sugiura D et al (2019) Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells. J Biol Chem 294:19896\u201319906. https:\/\/doi.org\/10.1074\/jbc.RA119.010379","journal-title":"J Biol Chem"},{"key":"8155_CR89","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","volume":"53","author":"N Acharya","year":"2020","unstructured":"Acharya N, Madi A, Zhang H et al (2020) Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity 53:658-671.e6. https:\/\/doi.org\/10.1016\/j.immuni.2020.08.005","journal-title":"Immunity"},{"key":"8155_CR90","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M et al (2020) Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 141:2031\u20132034. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"key":"8155_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB et al (2023) Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer 11:e006398. https:\/\/doi.org\/10.1136\/jitc-2022-006398","journal-title":"J Immunother Cancer"},{"key":"8155_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007409","volume":"12","author":"E Daetwyler","year":"2024","unstructured":"Daetwyler E, Wallrabenstein T, K\u00f6nig D et al (2024) Corticosteroid-resistant immune-related adverse events: a systematic review. J Immunother Cancer 12:e007409. https:\/\/doi.org\/10.1136\/jitc-2023-007409","journal-title":"J Immunother Cancer"},{"key":"8155_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, Burgers FH, Janssen JC et al (2024) Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur J Cancer Oxf Engl 207:114172. https:\/\/doi.org\/10.1016\/j.ejca.2024.114172","journal-title":"Eur J Cancer Oxf Engl"},{"key":"8155_CR94","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, Van Eijs MJM, May AM et al (2023) Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. Npj Precis Oncol 7:41. https:\/\/doi.org\/10.1038\/s41698-023-00380-1","journal-title":"Npj Precis Oncol"},{"key":"8155_CR95","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","volume":"42","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, de Groot JS, Fabriek BO et al (2024) Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 42:3713\u20133724. https:\/\/doi.org\/10.1200\/JCO.24.00191","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8155_CR96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm5663","volume":"15","author":"M Liu","year":"2023","unstructured":"Liu M, Wang X, Du X et al (2023) Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Sci Transl Med 15:eabm5663. https:\/\/doi.org\/10.1126\/scitranslmed.abm5663","journal-title":"Sci Transl Med"},{"key":"8155_CR97","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","volume":"22","author":"Q Liu","year":"2024","unstructured":"Liu Q, Liu M, Zou Z et al (2024) Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study. J Transl Med 22:803. https:\/\/doi.org\/10.1186\/s12967-024-05617-6","journal-title":"J Transl Med"},{"key":"8155_CR98","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1093\/oncolo\/oyae134","volume":"29","author":"S-J Liu","year":"2024","unstructured":"Liu S-J, Yan L-J, Wang H-C et al (2024) Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis. Oncologist 29:e1425\u2013e1434. https:\/\/doi.org\/10.1093\/oncolo\/oyae134","journal-title":"Oncologist"},{"key":"8155_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff M, Wang Y et al (2020) Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 8:e000604. https:\/\/doi.org\/10.1136\/jitc-2020-000604","journal-title":"J Immunother Cancer"},{"key":"8155_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2025.06.069","author":"G Bailly","year":"2025","unstructured":"Bailly G, Cohen A, Boccara F, Salem J-E (2025) Immune checkpoint inhibitor rechallenge after myocarditis: Time for reappraisal? Arch Cardiovasc Dis. https:\/\/doi.org\/10.1016\/j.acvd.2025.06.069","journal-title":"Arch Cardiovasc Dis"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-08155-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-025-08155-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-08155-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T20:34:56Z","timestamp":1764880496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-025-08155-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["8155"],"URL":"https:\/\/doi.org\/10.1007\/s00134-025-08155-x","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DL reports consultancies from CSL, Takeda and Biocryst outside the submitted work. VS reports consultancies and speaking fees from Boehringer-Ingelheim, EDF, Fresenius Kabi, Grifols, Ultragenyx (less than 10,000$) and research support from Grifols, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}